## IFF: International Flavors & Fragrances Inc. - XLB: Basic Materials

### Executive Summary

No thesis match: MRS_10 2.3% below STRENGTH zone (3.0-6.0%); PEG 2.29 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($65.31)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Cwm LLC Acquires 69,363 Shares of International Flavors & Fragrances Inc. $IFF**
- Source: MarketBeat | 20260102T030833 | Bullish | Relevance: 100%
- Cwm LLC significantly increased its stake in International Flavors & Fragrances Inc. (IFF) by 920.5% in Q3, purchasing 69,363 shares to hold a total of 76,898 shares valued at approximately $4.73 million. Institutional investors now own about 96.02% of the company, and analysts maintain a "Moderate Buy" rating with an average price target of $85.02 despite recent target adjustments. IFF reported Q3 EPS of $1.05 and declared a quarterly dividend of $0.40.

**2. Zacks Research Has Bullish Estimate for IFF Q2 Earnings**
- Source: MarketBeat | 20260101T110935 | Bullish | Relevance: 100%
- Zacks Research has increased its Q2 2026 EPS estimate for International Flavors & Fragrances (IFF) to $1.19, reflecting a modestly bullish outlook for the company's future earnings. This update comes after IFF recently surpassed consensus estimates for its last reported quarter but experienced a revenue decline and negative net margin, indicating mixed financial performance. Analysts currently have an average "Moderate Buy" rating for IFF with a mean target price of $85.02, while the company has also declared a quarterly dividend of $0.40.

**3. IFF Gains From Focus on Growth Despite Low Food Ingredient Volumes**
- Source: TradingView â€” Track All Markets | 20251231T160744 | Somewhat-Bullish | Relevance: 98%
- International Flavors & Fragrances (IFF) is strategically focusing on high-growth segments like Flavors, Fragrances, Health, Cultures & Food Enzymes, and expanding into emerging markets. Despite divestitures and currency risks expected to impact top-line growth in the near term, the company aims to enhance profitability through cost efficiencies, portfolio optimization, and disciplined capital allocation. These efforts are intended to strengthen its core business, balance sheet, and shareholder returns.

**4. Zacks Research Has Optimistic Outlook of IFF Q4 Earnings**
- Source: MarketBeat | 20260102T124255 | Bullish | Relevance: 97%
- Zacks Research has increased its Q4 2027 EPS estimate for International Flavors & Fragrances (IFF) to $1.10, leading to a "Moderate Buy" rating with an average price target of $85.02. IFF recently beat consensus EPS estimates for the last quarter and declared a $0.40 quarterly dividend. Institutional investors, including Dodge & Cox and Vanguard Group Inc., hold a significant portion of the stock.

**5. Enzyme Engineering Market Set for Rapid Growth and Trend**
- Source: openPR.com | 20260102T131153 | Bullish | Relevance: 83%
- The Global Enzyme Engineering Market is projected to grow significantly from USD 8.63 Billion in 2025 to USD 16.29 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.5%. This growth is driven by rapid innovation, increasing investments, and evolving regional dynamics. The market study offers insights into segmentation by type, application, and region, along with detailed profiles of key players like Novozymes A/S and DuPont de Nemours Inc.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 7 ($2.72M) |
| Sells | 1 ($0.75M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 1 |

**Top Holders:**
- Dodge & Cox Inc.: 14.4% (+5.5%)
- Vanguard Group Inc: 12.2% (+0.8%)
- Freemont Capital Pte: 9.9% (0.0%)
- Blackrock Inc.: 7.2% (-16.4%)
- State Street Corpora: 4.3% (+0.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.29 elevated, pricing in significant growth expectations. Forward P/E 15.2x stretched relative to 5% growth. Insider buying signal ($2.7M), management confidence. Institutional flow bullish (8 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $17.4B |
| Beta | 1.04 |
| 52W Range | $59.14 - $88.09 |
| Short Interest | 4.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.29 |
| Forward P/E | 15.2 |
| Current P/E | 16.0 |
| YoY Growth | 4.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.6% over 5 days). Below STRENGTH zone by 0.7pp (needs >3.0% for momentum thesis). MRS_5 at 1.1% confirms short-term momentum alignment. Below SMA200 (0.97x), long-term trend not supportive. RSI neutral at 60. OFD pattern: +SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.32% (CS: 79) | Neutral |
| RSI_14 | 59.7 | Neutral |
| MACD Histogram | 0.23 | Bullish |
| vs SMA20 | 1.031x | Above |
| vs SMA50 | 1.036x | Above |
| vs SMA200 | 0.972x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $68.03
- **Stop Loss:** $65.31 (4.0% risk)
- **Target:** $70.75 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 529
- **Position Value:** $35,987.87
- **Portfolio %:** 35.99%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | MOMENTUM (Zone F) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-17 (Est: $0.84)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.02 | $1.05 | +3.3% |
| 2025Q2 | $1.12 | $1.15 | +2.5% |
| 2025Q1 | $1.14 | $1.20 | +5.7% |
| 2024Q4 | $0.82 | $0.97 | +17.6% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*